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Objectives: Cancer survivors with GH deficiency (GHD) receive GH therapy (GHT) after 1+ year 
observation to ensure stable tumor status/resolution.
Hypothesis: Radiation therapy (RT) to brain, spine, or extremities alters growth response to GHT.
Aim: Identify differences in growth response to GHT according to type/location of RT.
Methods: The Pfizer International Growth Database was searched for cancer survivors on 
GHT for ≥5 years. Patient data, grouped by tumor type, were analyzed for therapy (surgery, 
chemotherapy, RT of the focal central nervous system, cranial, craniospinal, or total body 
irradiation [TBI] as part of bone marrow transplantation), sex, peak stimulated GH, age at GHT 
start, and duration from RT to GHT start. Kruskal-Wallis test and quantile regression modeling 
were performed.
Results: Of 1149 GHD survivors on GHT for ≥5 years (male 733; median age 8.4 years; GH peak 
2.8 ng/mL), 431 had craniopharyngioma (251, cranial RT), 224 medulloblastoma (craniospinal 
RT), 134 leukemia (72 TBI), and 360 other tumors. Median age differed by tumor group 
(P < 0.001). Five-year delta height SD score (SDS) (5-year ∆HtSDS; median [10th-90th percentile]) 
was greatest for craniopharyngioma, 1.6 (0.3-3.0); for medulloblastoma, 5-year ∆HtSDS 0.9 
(0.0-1.9); for leukemia 5-year ∆HtSDS, after TBI (0.3, 0-0.7) versus without RT (0.5, 0-0.9), direct 
comparison P < 0.001. Adverse events included 40 treatment-related, but none unexpected.
Conclusions: TBI for leukemia had significant impact on growth response to GHT. 
Medulloblastoma survivors had intermediate GHT response, whereas craniopharyngioma cranial 
RT did not alter GHT response. Both craniospinal and epiphyseal irradiation negatively affect 
growth response to GH therapy compared with only cranial RT or no RT. (J Clin Endocrinol 
Metab 105: 1–12, 2020)
Abbreviations: BMI, body mass index; CNS, central nervous system; GHD, GH defi-
ciency; GHT, GH therapy; KIGS, Pfizer International Growth Database; RT, radiation 
therapy; SAE, significant adverse event; SDS, SD score; TBI, total body irradiation.
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GH deficiency is common after radiation therapy (RT) for treatment of childhood cancer (1-3). 
RT for childhood cancer may include cranial or 
craniospinal irradiation for brain tumor, nasopharyn-
geal tumor, orbital tumor, or central nervous system 
leukemia; or total body irradiation (TBI) as prepar-
ation for bone marrow transplantation. GH deficiency 
(GHD) is often the only pituitary hormone deficiency 
after low-dose cranial irradiation (18-24 Gy) (4, 5). 
Higher RT doses (≥30 Gy) may lead to multiple pitu-
itary hormone deficiencies (deficiencies of GH, TSH, 
ACTH, and gonadotropins) (5-15). Risk, severity, and 
timing of onset of GHD are affected by the RT dose 
to the hypothalamus, not the pituitary (16-19). The 
risk of GHD after irradiation also increases with age 
younger than 10 years at time of tumor treatment (20, 
21). Precocious puberty or rapid progression of pu-
berty can also occur after cranial RT >18 Gy, with fe-
male sex and younger age at initial RT being the most 
important risk factors (22).
Of note, recommendations for GH replacement for 
GHD (based on expert opinion) are to wait 1  year 
or longer after completion of cancer therapy with no 
tumor growth before initiating GH therapy to ensure 
stable status/ resolution of tumor (3, 23, 24). GH treat-
ment (GHT) can be delayed longer depending on indi-
vidual patient circumstances. GHT is considered safe in 
patients after central nervous system (CNS) tumors (25, 
26) and is not associated with an increased risk of tumor 
recurrence or secondary tumors (27, 28). However, 
GHT should be considered only cautiously in persons 
with GHD after multiple recurrences, metastases, highly 
malignant tumors, or genetic predisposition to cancer 
(29, 30). Safety data have enabled earlier initiation of 
GHT to lengthen the duration of therapy. Suppression 
of precocious, early, or rapid puberty may additionally 
increase adult height (31-34).
Tumor therapies (chemotherapy, RT) may affect sub-
sequent growth of the skeleton (35-37). For instance, 
TBI is known to disrupt the epiphyses and reduce height 
potential in cancer survivors (36-38). Several studies 
have shown poor growth after fractionated RT (cranial, 
craniospinal, TBI), regardless of whether children devel-
oped GHD (39-44). It appears that GHT for GHD after 
craniopharyngioma increases adult height (45). Because 
irradiation damages both the epiphyses and the bone 
matrix, the skeleton may not demonstrate the growth 
response to GHT that is expected in children with idio-
pathic GHD (46).
We hypothesized that RT to brain, spine, or extrem-
ities alters linear growth response to GHT. We sought to 
assess the relative effects on growth response to GHT of 
cranial irradiation versus craniospinal irradiation versus 
RT to all growth centers (as in TBI) in a large group of 
childhood cancer survivors. The aim was to identify dif-
ferences in growth response to GHT according to type 
and location of RT. We also reviewed the occurrence 
of adverse events in these cancer survivors during GHT.
Patients and Methods
The Pfizer International Growth Database (KIGS) was 
searched for cancer survivors who had received GHT for at 
least 5  years. The 1149 cancer survivors were grouped by 
tumor type and data were analyzed for tumor therapy (sur-
gery, chemotherapy, RT [focal CNS, whole brain, craniospinal, 
or TBI as part of bone marrow transplantation]), sex, peak 
stimulated GH level, age at GHT start, and duration from RT 
to GHT start. Details of imaging, specific chemotherapeutic 
agents, and irradiation dosimetry administered were not avail-
able in the database. Within tumor diagnosis, patients were 
grouped by presence or absence of RT (Table 1).
Table 1. Characteristics of Patients With GH 
Deficiency in the KIGS Database who Have History 
of Childhood Cancer (n = 1149)
Male 733 64%
Median age of GHT start (y) 8.4 5.1, 11.6
Median peak GH (ng/mL) 2.8 0.5, 9.5
Median duration GHT (y) 7.5 5.5, 11.0
Median GH dose (mg/kg/wk) 0.18 0.12, 0.26
Tumor groups
Craniopharyngioma total 431 38%
 Cranial RT 137 32%
 No RT 268 62%
 Other/unknown 26 6%
Leukemia total 134 12%
 TBI 71 53%
 No TBI 52 39%
 Other/unknown 11 8%
Medulloblastoma total 224 19%
 Craniospinal RT 189 84%
 Other/unknown 35 16%
Other tumora 360 31%
Median and 10th, 90th percentiles are presented for continuous vari-
ables and Ns and % are for categorical variables. 
Abbreviations: GHT, GH therapy; RT, radiation therapy; TBI, total body 
irradiation.
“Other” tumor group and unknown RT groups are excluded from ana-
lysis.
aOther tumor diagnoses: germinoma (dysgerminoma, pinealoma) 
65; tumor of the pituitary/hypothalamic area 50; astrocytoma 41; 
ependymoma 35; glioma 35, solid tumor 27; nasopharyngeal tumor 
23; lymphoma other 7; Hamartoma 6; non-Hodgkin lymphoma 4; 
other cranial tumors 67.
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Children within each tumor group were categorized fur-
ther as prepubertal versus pubertal at GHT start, based on 
testicular volume >3 mL or Tanner stage for breast develop-
ment ≥2 as reported by the investigator to the KIGS database.
Statistical Methods
Height was expressed in SD score (SDS) units from 
the mean for age and sex (HtSDS). Likewise, change in 
height was expressed as delta HtSDS (∆HtSDS).
A stepwise regression model was used to identify 
covariates for inclusion in a quantile regression model 
of HtSDS at year 5 and ∆HtSDS at years 1 and 5 as 
the dependent variables. The independent covariates 
were the background and start of GH variables listed in 
Table 2. Backwards stepwise variable selection was used 
with cutoff values of P < 0.05 for entry and retention.
Quantile regression (47) was used to estimate the con-
ditional median of height SDS at year 5 and ∆HtSDS at 
years 1 and 5, including the significant covariates iden-
tified in the stepwise model (Table 3). The quantile re-
gression technique was chosen for the analyses because 
of the non-normal distributions of the data as tested 
with the Shapiro-Wilk test, invalidating assumption for 
ordinary least-squares regression. Quantile regression 
allows estimation and inference related to the median 
without making any distributional assumptions, in con-
trast to least-squares methods that rely on a normality 
assumption. The skewness of the height SDS variables 
may reflect meaningful heterogeneity. Kruskal-Wallis 
test was applied to the continuous background and start 
of GH variables and χ 2 test to the binary variables.
All statistical tests were carried out at the 2-sided 
significance level of 5%. Statistical analyses were per-
formed using SAS, version 9.4 (SAS Institute Inc., 
Cary, NC) using the QUANTREG procedure. The 
NPAR1WAY and FREQ procedures were applied for 
univariate testing of the background and start of GH 
variables presented in Table 2.
Results
Patient characteristics
Of 1149 cancer survivors with GHD (male 733; 
median age 8.4  years; median GH peak 2.8  ng/mL) 
treated with GH in KIGS, 431 had craniopharyngioma 
(251 with cranial RT), 224 had medulloblastoma (all 
with craniospinal RT), and 134 had leukemia (72 with 
TBI) (Tables 1 and 2). (The remaining survivors in each 
category did not receive any RT.) The other 360 pa-
tients were diagnosed with a variety of other tumors, 
which were treated with diverse regimens as clinically 
indicated for each of the different tumors. For clarity, 
given the diversity of their tumor therapies, their growth 
response to subsequent GHT was not included in this 
analysis. (A list of their diagnoses is shown as a foot-
note to Table 1.) No data were available in the database 
regarding adequacy of other hormone replacement (i.e., 
thyroid, hydrocortisone, vasopressin, or sex steroids).
Background characteristics according to tumor group 
are presented in Table  2 (top) including univariate 
testing of the variables. Table 2 (bottom) shows charac-
teristics according to tumor group at start of GHT and 
at last reported clinic visit. In the quantile regression 
model, response to GHT within tumor groups was as-
sociated with HtSDS at 5 years after controlling for pu-
berty status, age at tumor diagnosis, age at start of GH, 
mid-parental height SDS, HtSDS at start of GH, body 
mass index (BMI) SDS at GHT start, and dose at GHT 
start (mg/kg/week).
Height achieved during GHT according to 
tumor group
Craniopharyngioma (RT) was associated with 
the tallest 5-year HtSDS (median 5-year HtSDS esti-
mate =  -0.17) compared with the other tumor groups 
(P < 0.05), except for the craniopharyngioma (no RT) 
group (median estimate = -0.23, P = NS). The median 
5-year HtSDS for the leukemia (TBI) was significantly 
lower than the other tumor groups (median esti-
mate = -1.74, P < 0.05) (Fig. 1)
Factors significantly associated with taller 5-year 
HtSDS included dose at start of GH, HtSDS at start of 
GH, mid-parental HtSDS, and BMI SDS at GH start. 
Age at tumor diagnosis and age at GH start were nega-
tively associated with 5-year HtSDS (P < 0.05). Results 
are displayed in Table 3 (top).
Effects of initial pubertal status on HtSDS
Overall, patients who were pubertal at start of GHT 
had a significantly taller 5-year HtSDS compared with 
prepubertal patients, with an estimated difference of 
median 5-year HtSDS effect equal to 0.45 (P < 0.0001) 
(Table 4 bottom, Fig. 2). This was in spite of the pu-
bertal and prepubertal groups having a similar HtSDS 
at baseline. Results for each tumor group according to 
pubertal status at start of GHT are illustrated in Fig. 2. 
Interestingly, there was a significant interaction effect 
between tumor group and puberty status: patients in 
the prepubertal leukemia groups had a taller median 
5-year HtSDS compared with pubertal patients. An op-
posite effect was observed for the 3 other tumor groups 
in which prepubertal patients had a lower 5-year HtSDS 
than did the pubertal patients. The median age at GHT 
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start for pubertal patients was 9.3 years versus 6.4 years 
for prepubertal patients, P < 0.001.
Change in HtSDS during GH therapy according to 
tumor group
For the change in HtSDS (∆HtSDS) quantile regres-
sion models, response to GHT was significantly asso-
ciated with tumor group and characteristics at GHT 
start (pubertal status, age, weight SDS, and initial 
GH dose).
One- and 5-year median changes in height SDS 
(∆HtSDS) were greatest among tumor subgroups for 
craniopharyngioma, median (10th-90th percentile) 0.8 
(0.1-1.5) and 1.6 (0.3-3.0), without cranial RT (1- and 
5-year values 0.8 [0-1.8], 1.6 [0.3-3.0]), and with cra-
nial/focal RT (1- and 5-year values 0.7 [0.1-1.4], 1.5 
[0.2-2.9], P = NS) (Table 4 top). Delta HtSDS effects at 
5 years of GHT for craniopharyngioma (RT) and (no 
RT) were associated with largest response to GHT (me-
dian 5-year ∆HtSDS estimates 1.5, 1.6) compared with 
other tumor groups (P < 0.05) (Fig. 3).
For medulloblastoma, 1- and 5-year ∆HtSDS were 0.5 
(0.1-0.9) and 0.9 (0.0-1.9), respectively. This response 
was decreased compared with craniopharyngioma both 
with and without cranial RT (adjusted P < 0.0001).
For leukemia, 1-year ∆HtSDS after TBI was 0.3 (0.0-
0.7) compared with 0.5 (0.0-0.9) for leukemia without 
RT, adjusted P  =  0.011. Five-year ∆HtSDS after TBI 
was only 0.4 (-0.6 to 1.3) compared with 1.0 (0.2-1.9) 
for leukemia without RT (direct comparison adjusted 
P  <  0.0001). These responses were decreased com-
pared with craniopharyngioma at 1 and 5  years (ad-
justed P < 0.005). The median ∆HtSDS at 5 years for 
the leukemia (TBI) group was significantly less than 
for the other tumor groups (median 5-year ∆HtSDS es-
timate = 0.40, P < 0.05). The comparisons of median 
∆HtSDS at 1 and 5 years in the leukemia (no TBI) versus 
medulloblastoma groups were not significant.
Pubertal patients had a greater 5-year ∆HtSDS com-
pared with prepubertal patients, with an estimated dif-
ference of median effects equal to 0.26 (P < 0.024).
As expected, given the shorter time duration, the 
median 1-year ∆HtSDS effects were smaller compared 
with 5  years, with similar significant tumor group 
comparisons (Fig.  3). There was no significant effect 
of puberty on ∆HtSDS at 1  year of GHT. Increased 
∆HtSDS was observed with higher weight SDS, median 
∆HtSDS equal to 0.04. Dose at start of GHT was sig-
nificantly associated with 1-year ∆HtSDS. Older age 
at GH start was associated with significantly lower 
Table 3. Quantile Regression of 1- and 5-Year Change in Height SDS (∆HtSDS) and Height in SD Units From 
the Mean for Age (HtSDS) at 5 Years of GH Therapy, for Childhood Cancer Survivors With and Without 
Irradiation in GH-Treated Cancer Survivors With GH Deficiency Entered in the KIGS Database, Quantile 0.50 
(median)
Exploratory Variable
1-Year ∆HtSDS 5-Year ∆HtSDS
HtSDS at 5 Years  
of GH
Estimate P Value Estimate P Value Estimate P Value
Craniopharyngioma (RT) 0.75 <0.0001 2.24 <0.0001 -0.17 0.47
Craniopharyngioma (no RT) 0.80 <0.0001 2.25 <0.0001 -0.23 0.32
Leukemia (TBI) 0.27 0.015 0.90 0.0004 -1.74 <0.001
Leukemia (no TBI) 0.50 0.0001 1.69 <0.0001 -0.77 0.002
Medulloblastoma 0.47 <0.0001 1.48 <0.0001 -1.02 <0.001
Craniopharyngioma RT  
vs craniopharyngioma no RT
-0.05 0.47 -0.01 0.96 0.05 0.68
Craniopharyngioma RT vs leukemia (TBI) 0.48 <0.0001 1.34 <0.0001 1.56 <0.001
Craniopharyngioma RT vs leukemia (no TBI) 0.25 0.012 0.56 0.0004 0.59 <0.001
Craniopharyngioma RT vs medulloblastoma 0.28 <0.0001 0.76 <0.0001 0.85 <0.001
Craniopharyngioma no RT vs leukemia (TBI) 0.53 <0.0001 1.35 <0.0001 1.51 <0.001
Craniopharyngioma no RT vs leukemia (no TBI) 0.30 0.003 0.56 0.0004 0.54 <0.001
Craniopharyngioma no RT vs medulloblastoma 0.33 <0.0001 0.76 <0.0001 0.79 <0.001
Leukemia (TBI) vs leukemia (no TBI) -0.23 0.011 -0.79 <0.0001 -0.97 <0.001
Leukemia (TBI) vs medulloblastoma -0.20 <.0001 -0.58 <0.0001 -0.72 <0.001
Leukemia (no TBI) vs medulloblastoma 0.03 0.72 0.21 0.15 0.25 0.018
In puberty 0.57 <.0001 1.84 <0.0001 -0.56 0.019
Prepubertal 0.55 <.0001 1.58 <0.0001 -1.01 <0.001
In puberty vs prepubertal 0.02 0.70 0.26 0.024 0.45 <0.001
Age at GHT start (y) -0.04 0.0003 -0.07 <0.0001 -0.06 0.002
Weight (SDS) at GHT start 0.04 0.003 0.07 0.39 NA  
Dose at GHT start (mg/kg/wk) 1.56 <0.0001 1.68 0.014 2.36  <0.001
Values shown are parameter estimates and P values from quantile regression at the 50th percentile.
Abbreviations: GHT, GH therapy; RT, radiotherapy; SDS, SD score; TBI, total body irradiation.
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∆HtSDS of -0.04 for each 1-year increment in age at 
GH start. Results for ∆HtSDS at years 1 and 5 are dis-
played in Table 4 (top).
Dose at start of GHT was significantly associated 
with an increased ∆HtSDS. Older age at GHT start was 
associated with a significantly lower ∆HtSDS of -0.07 
for each 1-year increment in age at GHT start.
Growth for prepubertal cancer survivors 
(Table 4 bottom)
One- and 5-years median HtSDS were greatest 
among tumor subgroups for craniopharyngioma, me-
dian (10th-90th percentile) 0.8 (0.1-1.5) and 1.6 (0.3-
3.0). For medulloblastoma, 1- and 5-year ∆HtSDS were 
0.5 (-0.1 to 0.8) and 0.9 (0.1-1.7), respectively. For 
leukemia, 1-year ∆HtSDS after TBI was 0.3 (0.0-0.7) 
compared with 0.5 (0.0-0.9) for leukemia without RT. 
Five-year ∆HtSDS after TBI 0.4 (-0.6 to 1.3) compared 
with 1.0 (0.2-1.9) for leukemia without RT (direct com-
parison P < 0.05).
Safety/adverse events
There were no new serious adverse events (SAE) 
that have not been previously reported. Forty patients 
reported a treatment-related SAE (Table 5); none of the 
SAE were unexpected. Drug was withdrawn in 18 of 
the 40 patients who had treatment-related SAEs, mainly 
from those with craniopharyngioma recurrence. Dose 
was delayed in 9 while SAEs resolved. In the others, 
there was no change in GH therapy.
Overall, there were 1190 adverse events reported in 
420 patients, with 325 considered as serious in 193 pa-
tients. Death was reported for 20 patients, of whom 4 
deaths occurred after cessation of GHT (intracranial 
hemorrhage, suicide, T-cell lymphoma, and bone neo-
plasm) (Table 6).
Treatment discontinuation
Of the entire group of 1149 patients, 656 reported 
discontinuation of GHT. The most frequent explan-
ations for discontinuation included completion of linear 
growth (N = 341, 52%), followed by poor height vel-
ocity (154, 23.5%), adverse event (22, 3.4%), lost to 
follow-up (20, 3.0%), and other reasons (119, 18.1%). 
The majority of patients who discontinued in the “other 
reasons” category withdrew for the following reasons: 
decision made by patient or parent (N = 55), no funds for 
GH (N = 16), change of product (N = 8), nonadherence 
(N = 6), not responding to treatment (N = 6), patient 
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Figure 1. Height SD from the mean (HtSDS) at baseline before GH therapy (GHT) and after 5 years of GHT in GH-deficient childhood cancer 
survivors, according to tumor subgroup. SDS, SD score.
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Table 4. Comparison of 1- and 5-Year Height in SDS from the Mean for Age (HtSDS) and Change in Height 
SDS (∆HtSDS) During GH Therapy, for Childhood Cancer Survivors With and Without Irradiation
Tumor Groups: All Patients
Median Delta Height SDS (10th, 90th percentiles)
HtSDS at  
Start of GH 1-Year ∆HtSDS 5-Year ∆HtSDS
HtSDS at  
5 Years of GH
Craniopharyngioma (RT + no RT) -2.3  
(-3.9, -0.4)
0.8  
(0.1, 1.5)
1.6  
(0.3, 3.0)
-0.6  
(-2.6, 1.4)
Leukemia (TBI) -2.1  
(-3.2, -1.0)
0.3  
(0.0, 0.7)
0.4  
(-0.6, 1.3)
-1.8  
(-3.2, -0.5)
Leukemia (no TBI) -2.2  
(-3.5, -0.9)
0.5  
(0.0, 0.9)
1.0  
(0.2, 1.9)
-1.2  
(-2.6, 0.3)
Medulloblastoma (craniospinal RT) -2.0  
(-3.6, -0.8)
0.5  
(0.1, 0.9)
0.9  
(0.0, 1.9)
-1.0  
(-3.0, 0.4)
Tumor Groups: Prepubertal Patients
Craniopharyngioma (RT + no RT) -2.5a  
(-4.3, -0.7)
0.8  
(0.1, 1.7)
1.6  
(0.3, 3.3)
-0.8a  
(-2.9, 1.4)
Leukemia (TBI) -2.0  
(-3.2, -1.2)
0.3  
(0.0, 0.9)
0.4  
(0.0, 1.7)
-1.4  
(-2.7, -0.5)
Leukemia (no TBI) -2.2  
(-3.2, -1.6)
0.5  
(0.1, 0.9)
1.1  
(-0.7, 1.8)
-1.1  
(-2.3, 0)
Medulloblastoma (craniospinal RT) -2.4  
(-4.0, -1.4)
0.5  
(-0.1, 0.8)
0.9  
(0.1, 1.7)
-1.6  
(-3.5, -0.2)
Top panel includes all patients; bottom panel includes only patients who were prepubertal at start of GHT.
Abbreviations: RT, radiation therapy; TBI, total body irradiation; SDS, SD score.
aData are presented as median delta height SD score (10th, 90th percentiles).
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Figure 2. Height SD from the mean (HtSDS) at 5 years of GH therapy (GHT) in prepubertal compared with pubertal GH-deficient childhood cancer 
survivors, according to tumor subgroup. SDS, SD score.
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moved (N = 5), study closure (N = 3), treatment trial 
(N  =  2), closing center (N  =  2), change of diagnosis 
(N = 1), and other unknown (N = 15). The median dur-
ation of GHT at time of discontinuation for all reasons 
was 7.7 years, ranging from 6.4 years for adverse event 
to 8.2 years for near-adult height reached.
Discussion
The current study shows that at 1 and 5 years of GHT, leu-
kemia survivors with GHD who had received TBI as part 
of preparation for bone marrow transplantation experi-
enced the most significant impact of RT on their growth 
response to GHT compared with other tumor survivors 
with GHD. After medulloblastoma (typically treated 
with craniospinal RT), survivors had an intermediate 
growth response to GHT. After craniopharyngioma 
(treated either without RT or with cranial RT), survivors 
did not have reduced growth response to GHT. Thus, 
we observed that both craniospinal RT and general epi-
physeal irradiation (TBI) were associated with restricted 
linear growth response during GH treatment for GHD 
compared with cranial RT only or no RT.
Several studies (that were smaller than the current 
one) have observed that vertebral growth slows after 
spinal irradiation or TBI, which are tumor therapies 
that contribute to short stature (35-37). Additional 
factors contributing to poor growth velocity in tumor 
survivors may include age at tumor therapy, hypothy-
roidism, sex, altered pubertal timing, GH insufficiency, 
secondary adrenal insufficiency, chronic unresolved 
illness, undernutrition, depression, and suppressive ef-
fects of chronic steroid therapy for graft-versus-host 
disease (41, 48). GH therapy after craniopharyngioma 
clearly increases adult height (45).
GHD in craniopharyngioma represents a probable 
direct effect of tumor burden as well as resulting from 
surgery in the hypothalamic-pituitary region. Many pa-
tients with craniopharyngioma demonstrated slowing 
of linear growth before any tumor therapy (49, 50). 
Tumor involvement of the hypothalamus may partially 
explain why the patient groups with craniopharyngioma 
receiving RT and without RT in the current study 
had similar baseline HtSDS and similar growth re-
sponses to GHT. GH therapy is often started in GHD 
craniopharyngioma survivors by 1  year after cranial 
surgery, before observing the effects of GHD on height.
In contrast, development of GHD after 
medulloblastoma or leukemia represents an effect of 
RT. In addition, start of GHT in GHD survivors of 
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Figure 3. Change in height SD from mean baseline HtSDS (∆HtSDS) during GH therapy (GHT) in GH-deficient childhood cancer survivors at 1 and 
5 years of GHT, according to tumor subgroup. SDS, SD score.
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medulloblastoma or leukemia is usually delayed for 
more years after RT; thus, such patients may have sig-
nificant growth deficit by the start of GHT.
Several studies have shown poor growth after frac-
tionated RT (cranial, craniospinal, or TBI), regard-
less of whether children developed GHD (40-44). In 
addition, growth response to GHT is less after RT to 
epiphyseal growth centers (36). Irradiation damages 
both the epiphyses and the bony matrix; thus, the 
skeleton may not demonstrate the growth response 
to GHT that is expected in children with idiopathic 
GHD (46).
The observation that leukemia survivors with GHD 
who received no RT grew no better during GHT 
than medulloblastoma survivors (who had received 
craniospinal RT) suggests long-term effects on growth 
potential by other factors in leukemia therapy (such as 
steroids or chemotherapy). Several studies have observed 
absence of catch-up growth after completion of therapy 
in leukemia survivors who had received no RT. Lack of 
catch-up growth was associated with reduced adult height 
(51, 52). Specific causative factors were not identified; 
however, younger age at leukemia diagnosis and greater 
chemotherapy intensity were associated with shorter adult 
height (51). It is possible that GHT may not resolve all of 
the growth deficit in leukemia survivors.
It is unclear whether GHT can compensate for the ef-
fects of RT on epiphyseal growth. A comparison of cra-
nial compared with craniospinal RT regarding growth 
response to GHT has been performed in small cohorts 
only (44, 53-57). In addition, comparisons within a 
common study have not been made of the effects of cra-
nial and craniospinal RT to those of TBI on response 
to GHT, nor to the growth response to GH in children 
with idiopathic GHD without cancer history.
The strengths of the current analysis derive from the 
large number of patient observations in each tumor 
group and the at least 5-year duration of observed GHT 
response. The study is limited by not having access in the 
database to details of imaging, tumor treatment details, 
Table 5. Treatment-Related Serious Adverse Effect 
Reported in 40 Cancer Survivors Treated With GH 
for GH Deficiency
Category Diagnosis
No. of 
Pa-
tients
General and 
metabolic
Fatigue 1
 Type 1 diabetes mellitus 2
 Type 2 diabetes mellitus 1
Musculoskeletal Muscle spasm 1
 Scoliosis 3
 Hip epiphysiolysis 1
 Peripheral edema 1
Neurologic Headaches 4
 Epilepsy 2
Tumor PNET progression 1
 Recurrence of 
craniopharyngioma 
20
 Recurrence of Ewing 
sarcoma 
1
 Recurrence of optic glioma 3 (1 
death)
Abbreviation: PNET, primative neuroectodermal tumor.
Table 6. Cause of Death in GH-Treated Cancer Survivors With GH deficiency, According to Tumor Group
Primary Diagnosis
N  
(male, 
N) 
RT  
(N)
Age at GH 
Start (y)a
GH Dose  
(mg/kg/wk)
Age at 
SAE (y)a Cause of Death
Craniopharyngioma 6 (2) 3 C  
3 none
7.1  
(4.0-10.7)
0.14  
(0.05-0.20)
16.1  
(12.1-18.6)
Craniopharyngioma 
recurrence (n = 2)  
Intracranial hemorrhage 
(n = 1)  
Unknown (n = 3)
Leukemia 2 (2) 1 C and G 
1 TBI
8.6  
(7.6-9.5)
0.18  
(0.13-0.22)
16.6  
(13.9-19.3)
Oligodendroglioma  
Suicide
Medulloblastoma 4 (3) 1 C  
3 CS
7.7  
(3.9-8.8)
0.12  
(0.05-0.19)
15.0  
(11.6-16.8)
Tumor recurrence  
Colorectal cancer  
Pneumonia  
Sudden collapse
Others 8 (4) 4 C  
1 CS  
2 TBI  
1 none
7.5  
(4.5-11.4)
0.21  
(0.10-0.23)
16.6  
(10.6-22.9)
Tumor recurrence (n = 2)  
Brain stem syndrome  
Hepatocellular carcinoma  
T-cell lymphoma  
Myelodysplastic syndrome 
Bone neoplasm  
Epilepsy
Abbreviations: C, cranial radiation therapy; CS, craniospinal radiation therapy; G, gonadal radiation therapy; TBI, total body irradiation; SAE, serious 
adverse event.
aMedian (10th-90th percentiles)
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body proportions such as sitting height measurements, 
details of timing of puberty, and other pituitary hormone 
dysfunction(s) and their treatment. These limitations are 
inherent in an analysis from a registry, where not all de-
tails from each patient were entered. Details about body 
proportions would be particularly useful in evaluating 
response to GHT in medulloblastoma patients who are 
treated with craniospinal RT.
It is likely that the growth response to GHT in cancer 
survivors with GHD could be associated with the RT 
dose to the hypothalamus or affected by additional 
factors not available in the database (precise pubertal 
timing, other hormone replacements, bone maturation).
Confounders in the analysis of the growth response 
to GHT are age and variation in the onset and tempo 
of puberty. Children who are younger at the onset of 
GHT have a faster initial growth velocity in response 
to GH than do those who are older at onset of GHT. In 
addition, timing of onset of puberty is often earlier after 
cranial RT, and rate of progression of puberty is often 
faster after cranial RT than in children without history 
of RT (33). These factors were not consistently reported 
in the KIGS database and could potentially affect our re-
sults. However, we did not observe less growth achieved 
over 5  years in our patients who received cranial RT 
compared with those without RT history.
Cancer survivors who were pubertal at the start of 
GHT generally reached a taller HtSDS after 5  years 
of GHT than did those who were prepubertal at start 
of GHT. Most likely, this was related to the pubertal 
growth spurt augmenting the growth response to GHT. 
Patients treated for leukemia with bone marrow trans-
plantation with TBI were the exception. Their 5-year 
change in HtSDS was less than the prepubertal leu-
kemia TBI group, perhaps because TBI (irradiation to 
all epiphyses) blunted the pubertal growth spurt.
Guidelines from the Endocrine Society, the Children’s 
Oncology Group, and from transplant groups recom-
mend that in childhood cancer survivors, monitoring 
(height, weight, BMI, and puberty) should be every 
6 months until adult height is achieved, then yearly in 
individuals who are at risk of GHD (cranial irradiation 
>18 Gy) (3, 54, 58). Per Pediatric Endocrine Society 
guidelines, “For GH initiation after completion of 
tumor therapy with no evidence of ongoing tumor, a 
standard waiting period of 12 months to establish ‘suc-
cessful therapy’ of the primary lesion is reasonable but 
can also be altered depending on individual patient cir-
cumstances” (23). Initial recommended dose of GHT in 
children with GHD is 0.16-0.24 mg/kg per week div-
ided daily (22-35 μg/kg per day), administered subcuta-
neously, with individualization of subsequent dosing 
(23, 25). The GH doses in the current report were 
generally near the lower end of this dose range. We sug-
gest that GH doses be adjusted to achieve target IGF-I 
in the mid-normal range in cancer survivors (59), and 
that screening for additional endocrinopathies should 
be performed at least annually after RT (20). Adverse 
effects of GHT are rare, occur soon after therapy ini-
tiation, and include benign intracranial hypertension, 
slipped capital femoral epiphysis, scoliosis progression, 
or carpal tunnel syndrome (23). If coexisting ACTH de-
ficiency is present, cortisol therapy should be started be-
fore GH or thyroid therapies.
Long-term surveillance is mandatory for childhood 
CNS tumor survivors treated with GH (3, 23, 25). 
It is important for clinicians to give patient-families 
realistic expectations of response to GHT so they can 
make appropriate, well-informed risk-benefit deci-
sions (and also help prevent loss of adherence to GHT 
from disappointment that height is not increasing as 
anticipated). Those with a history of spinal RT should 
be prepared for suboptimal height increases as well as 
disproportionate elongation of legs relative to trunk. 
Otherwise, parents may request escalation of GHT 
doses, which still will not overcome RT effects but 
may increase risk for potential side effects. If families 
have appropriate expectations regarding limitations 
of GHT, hopefully there will be less pressure to pursue 
these strategies.
Clearly, GHT is effective in increasing growth 
achieved after tumor therapy in cancer survivors who 
have GHD. That less growth response is observed 
after leukemia with no RT, spinal RT, or TBI than 
in children without these treatments does not contra-
vene use of GHT. Timing of onset and rate of pro-
gression of puberty may alter potential height gain. 
Use of GnRH analog therapy may prolong the cancer 
survivor’s ability to respond to GHT (but may in-
crease disproportion). The goal of GHT in these chil-
dren is to assist cancer survivors in returning toward 
normal stature.
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